cytarabine/gemtuzumab ozogamicin/mitoxantrone

Known as: ARA-C/CMA-676/DHAD 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
012320012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
 
Is this relevant?
2011
2011
Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients with acute… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
 
Is this relevant?
2008
2008
BACKGROUND Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia (AML). We evaluated… (More)
Is this relevant?
2007
2007
We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with cytarabine and mitoxantrone in the treatment of… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2007
2007
BACKGROUND In this study, the effectiveness and safety of combining gemtuzumab ozogamicin (GO) with an abbreviated schedule of… (More)
Is this relevant?
2005
2005
This open-label, dose-escalation study evaluated the safety and efficacy of single-agent gemtuzumab ozogamicin, a humanized anti… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2001
2001
The earliest description of what later proved to be hepatic veno-occlusive disease appeared in 1911. These studies described… (More)
Is this relevant?